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Abstract
Objectives. To estimate the preferences of osteoporotic patients for medication attributes, and analyse
data from seven European countries.
Methods. A discrete choice experiment was conducted in Belgium, France, Ireland, the Netherlands,
Spain, Switzerland and the UK. Patients were asked to choose repeatedly between two hypothetical
unlabelled drug treatments (and an opt-out option) that varied with respect to four attributes: efficacy in
reducing the risk of fracture, type of potential common side effects, and mode and frequency of admin-
istration. In those countries in which patients contribute to the cost of their treatment directly, a fifth
attribute was added: out-of-pocket cost. A mixed logit panel model was used to estimate patients’
preferences.
Results. In total, 1124 patients completed the experiment, with a sample of between 98 and 257 patients
per country. In all countries, patients preferred treatment with higher effectiveness, and 6-monthly subcuta-
neous injection was always preferred over weekly oral tablets. In five countries, patients also preferred a
monthly oral tablet and yearly i.v. injections over weekly oral tablets. In the three countries where the out-of-
pocket cost was included as an attribute, lower costs significantly contributed to the treatment preference.
Between countries, there were statistically significant differences for 13 out of 42 attribute/level interactions.
Conclusion. We found statistically significant differences in patients’ preferences for anti-osteoporosis
medications between countries, especially for the mode of administration. Our findings emphasized that
international treatment recommendations should allow for local adaptation, and that understanding individ-
ual preferences is important if we want to improve the quality of clinical care for patients with osteoporosis.
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Rheumatology key messages
. Osteoporotic patients are willing to pay or to trade treatment efficacy for their preferred mode of administration.
. Significant heterogeneity in patients’ preferences for osteoporotic drug treatment and country differences were
observed.
Introduction
It is recognized that clinical and policy decision should
include the patient’s perspective. Product development
and acceptance could also benefit from knowledge
about what patients value and prefer regarding their treat-
ment [1]. Patients’ preferences can also be useful for the
appraisal of health-care programmes, alongside the clin-
ical, economic, social and ethical considerations. Recent
examples include the attention to and inclusion of the pa-
tient’s perspective in health technology assessment,
coverage decisions and clinical practice guideline devel-
opment [24]. Health professionals may find that know-
ledge of patients’ preferences and how patients value
different aspects of care helps them to improve disease
management. Patients who are more involved in decision-
making could have better therapy adherence [5]. In re-
sponse, an increasing number of studies elicit patients’
preferences in the health-care setting. In particular, the
application of discrete choice experiments (DCEs) as a
method of eliciting patients’ preferences has increased
in recent years [6, 7]. A DCE is a stated-preference
method in which respondents are asked to repeatedly
choose between hypothetical treatment options that sys-
tematically differ in several attributes of interest, such as
effectiveness, cost, side effects and mode of administra-
tion. DCEs are a useful method for quantifying the relative
importance of attributes and the trade-offs that respond-
ents make between them [5].
Results from a recent DCE study [8] to assess the pref-
erences of osteoporotic patients for drug treatment in
Belgium suggest that osteoporotic patients preferred
treatment modes of 6-month s.c. injection and an oral
monthly tablet, and disliked gastrointestinal disorders
as side effects. In addition, patients were willing
to trade treatment effectiveness or a personal monet-
ary contribution for their preferred mode of
administration.
Little is known about how comparable patients’ prefer-
ences are between countries. The previous study [8] was
carried out in two osteoporosis centres in Belgium. An
editorial accompanying the previous study [9] suggested
that the generalizability of the results should be further
investigated. We therefore extended the previous study
to six additional Western European countries. The aim of
this paper was to evaluate and compare the preferences
of osteoporotic patients from several European countries
for medication attributes. This study will therefore not only
reveal whether patients’ preferences differ between a
number of countries, but will also provide further insights
for policy-makers and health professionals into the gener-
alizability of patients’ preferences for osteoporotic drug
treatment.
Methods
We used a DCE to examine preferences for drug treat-
ment among patients with, or at risk of, osteoporosis. In
the DCE, patients were asked to make a series of hypo-
thetical choices between two unlabeled drug alternatives
that varied along several attributes of interest (and a no
treatment option). State of the art methods recommended
in DCE guidelines were used to select the attributes and
levels, to design the DCE and to conduct the statistical
analysis [5, 10]. Details of the DCE development can be
found in a previous publication [8], and access to the
English language questionnaire is available online as an
additional file [8]. A brief description of the various com-
ponents of the DCE is provided below.
Attributes and levels
The attributes included in the DCE were selected from the
results of qualitative research [11, 12]. Patient group dis-
cussions in Belgium and the Netherlands were used to
prioritize a list of 12 potentially important osteoporosis
drug therapy attributes. The list was based on existing
literature and expert opinion. Patients identified five im-
portant attributes, and all were included in the DCE: ef-
fectiveness, side effects, mode of administration,
frequency of administration and, in Belgium, out-of-
pocket cost (see Table 1). The out-of-pocket cost attribute
was only included in countries where patients pay out-of-
pocket for osteoporotic treatment (i.e. Belgium, Ireland
and Switzerland). Levels for each attribute were assigned
based on current treatment, using a literature review and
expert opinion (n= 5). For the side effects attribute, the
three levels were related to the nature of common side
effects.
Experimental design
The set of treatment options to be presented to the re-
spondents was based on an experimental design.
Specifically, we used a Bayesian efficient design to maxi-
mize the D-efficiency of the chosen choice sets using
Ngene software (Version 1.1.1, http://www.choice-met-
rics.com). A Bayesian efficient design aims to maximize
the precision of the estimated parameters of the attributes
for a given number of choice tasks by incorporating a
priori information about the sign and value of parameters.
Parameter estimates derived from a pilot study (n= 10)
were used as a priori information to construct the choice
sets. Fifteen choice tasks were created in which respond-
ents were asked, in each case, to choose between two
unlabelled drug alternatives (A and B) and a no treatment
option. The experimental design was restricted to include
only realistic combinations of mode and frequency of ad-
ministration. There was a small correlation between
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attributes in the experimental design because it was opti-
mized on efficiency. One of the choice tasks was repeated
at the end of the choice tasks to assess testretest reli-
ability of respondents’ choices. Each respondent there-
fore received 16 choice tasks. An example of a choice
task is shown in Fig. 1.
Questionnaire, data collection and patients’
recruitment
The questionnaire was paper-based. The attributes and
levels were first described and an example of a completed
choice task was included. After respondents had com-
pleted the 16 choice tasks, they were asked how difficult
they found the tasks on a seven-point Likert scale. Data
on patients’ demographics and socio-economic charac-
teristics and experiences with osteoporosis and treat-
ments were also collected. Three versions of the
questionnaire were designed that differed in attribute
presentation to control for an attribute ordering effect.
The questionnaire was developed in English by a work-
ing group that included a patient, DCE experts and clinical
experts. This version was approved by two native English
speakers who are osteoporosis experts. The questionnaire
was translated into three languages (French, Spanish and
Dutch) by a medical translation company specializing in
patient-reported outcome measures translation (Pharma
Quest Ltd, Oxford, UK). The four languages covered the
languages spoken across the countries in our sample.
Each language version was checked and approved by at
least two native speakers. The English survey was pilot-
tested (n=10) to check for any problems with interpretation
and face validity; only minor changes to layout were made.
The study was conducted in seven European
countries—Belgium, France, Ireland, the Netherlands,
Spain, Switzerland and the UK—between March and
October 2012. The analysis for Belgian patients has
been published previously [8]. Patients with, or at risk
for, osteoporosis to whom medication (or lifestyle
changes) was at least proposed were consecutively re-
cruited during outpatient clinics. The questionnaire was
completed by the patient at the clinic, or at home and
returned in a postage-paid envelope. Calculation of opti-
mal sample sizes was not possible, as they depend on the
true values of the unknown parameters estimated in the
DCE [13]. Hence, a minimum of 100 patients per country
was targeted, which was sufficient based on common
rules-of-thumb for minimum sample size [14].
Approval for this study was obtained from the Medical
Ethics Committee of the Academic Hospital Maastricht
TABLE 1 List of attributes and levels
Efficacy in reducing the risk of future fractures (%)
20
30
40
50
Possible side effects (affecting 1 in 50 patients)
Gastrointestinal disorders
Flu-like symptoms
Skin reactions
Mode of administration
Oral tablet
s.c. injection
i.v. injection
Frequency of administration
Weekly
Monthly
Every 3 months
Every 6 months
Yearly
Cost to you (per month)
E5
E15
E25
E40
FIG. 1 Example choice set of DCE experiment
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and Maastricht University. A team from this university
coordinated the project. Participants gave informed writ-
ten consent according to the 1964 Declaration of Helsinki.
Additional local ethics approval was obtained from those
participating centres that required ethics approval for a
DCE study, that is, the Research Ethics Committee of
the Sligo University Hospital, the Southampton Joint
Ethics Committee, the CEIC-Parc de Salut Mar
(Committee of Ethics and Clinical Investigation) and the
Commission cantonale d’e´thique de la recherche of
Geneva.
Statistical analyses
Data analysis was carried out using Nlogit software, ver-
sion 5.0. Data of patients who completed less than five
choice sets were excluded. To allow for preference het-
erogeneity within each country, a mixed logit model was
estimated [15]. This model is based on the assumption
that parameters are randomly distributed in the popula-
tion, and captures heterogeneity by estimating the stand-
ard deviation of the parameter’s distribution. We used a
panel mixed logit model to account for the panel nature of
the data as each patient completed 15 choice sets.
The following utility model was estimated for each
country c:
Vij ¼ b0 þ b1 þ Z1i
 
efficacyj þ b2 þ Z2i
 
costj
þðb3 þ Z3iÞoral1Mj þ ðb4 þ Z4iÞsub3Mj
þ ðb5 þ Z5iÞsub6Mj þ ðb6 þ Z6iÞint3Mj
þðb7 þ Z7iÞint1Yj þ ðb8 þ Z8iÞflusymptj
þ ðb9 þ Z9iÞskinreactj þ "ijt;
where V represents the systematic relative utility, b0 is the
constant reflecting the average preference for selecting
treatment relative to no treatment across the different
choice sets, b1b9 are coefficients of the attributes levels
indicating the relative preference for each attribute level,
and Z1iZ9i are error terms capturing individual-specific
unexplained variation around the mean. Effects coding
was used to describe the categorical variables (mode
and frequency of administration, and side effects). Using
effect coding, mean attributes are normalized to zero and
preference weights are relative to the mean effect of the
different levels of the attribute. A positive sign for a given
level therefore indicates a level has a positive effect on
utility compared with the mean effect of the attribute. If
the 95% CI around two levels did not overlap, the differ-
ences between the preference weights were considered
to be statistically different. Although the attributes efficacy
in reducing the risk of future fractures and out-of-pocket
contribution are presented as discrete levels in the experi-
ment, they were coded as continuous variables in the
model with a linear specification, allowing willingness to
pay estimates and providing a better model fit.
We took preference heterogeneity into account by spe-
cifying all parameters as random parameters. The random
parameters for the cost and efficacy were drawn from a
log-normal distribution in order to constrain the parameter
on the negative and positive scale, respectively [15].
All other random parameters were drawn from a normal
distribution. If the standard deviation of the random par-
ameters was significantly different from zero, this was in-
terpreted as evidence of significant preference
heterogeneity for the attribute within the population. The
estimation was conducted by using 2000 Halton draws.
Model fit was assessed using log-likelihood, McFadden’s
pseudo-R2 and the Akaike Information Criterion.
Two subgroups analyses were conducted to investigate
potential differences between countries. We wish to allow
preferences to be systematically different in countries with
the cost attribute (Belgium, Ireland and Switzerland) and in
countries without (France, the Netherlands, Spain, the
UK). To assess whether preferences were significantly dif-
ferent between countries within each subgroup (with and
without a cost attribute), a joint model was estimated
using interaction terms to capture potentially systematic
differences in preference between countries. Preferences
were considered to vary across countries within a sub-
group if the parameters estimated for the interaction
terms were statistically different from zero (5% level). To
take scale heterogeneity into account and thus to control
for the fact that differences between countries can also be
due to difference in the unobserved error scale, a normally
distributed random component was added for each coun-
try dummy [16]. This allowed us to test whether a signifi-
cant difference in the interaction terms reflected a
systematic difference in preference, and not merely a dif-
ference in the scale of the random error between
countries.
In addition, at the country level we analysed the impact
of previous fractures on patients’ preferences that was
shown to be a relevant covariate in previous research [8,
17, 18]. To assess the significance of the differences be-
tween patients with and without previous fractures, a joint
model per country was estimated using interaction terms.
A normally distributed random component was added for
the dummy variable designed for previous fractures.
Results
Patients’ characteristics
A total of 1201 questionnaires were returned. Of these,
1124 questionnaires were sufficiently completed (i.e. at
least 10 choice tasks completed) and included in the ana-
lysis, with a sample of between 98 and 257 patients per
country. The respondents had a mean age of 65.0 years,
and 85.3% were female. Of all respondents, 73.9% were
diagnosed with osteoporosis, 52.1% had a prior fracture
and 55.4% received osteoporosis drug treatment. Socio-
demographics and health characteristics are shown in
Table 2 by country. A total of 85.2% of the respondents
(country range: 80.989.4%) selected the same alternative
in the testretest exercise. On average, the task was seen
as relatively easy, with an average score of 3.04 (country
range: 2.623.41), based on responses to a seven-point
scale (one for extremely easy and seven for extremely
difficult). Both testretest reliability and the perceived
level of task difficulty are in line with previous studies [19].
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Patients’ preferences
The panel mixed logit model results are presented in
Table 3. The estimated coefficients for efficacy and
costs (when included) were statistically significant in all
countries. The positive sign of the efficacy parameter in-
dicates that treatment utility increases with higher treat-
ment efficacy and the negative sign of the cost parameter
indicates that respondents prefer to pay less for
treatment.
In all countries, patients preferred a 6-monthly subcuta-
neous injection over weekly oral tablets (see Fig. 2). In
most countries, patients also preferred a monthly oral
tablet and/or yearly i.v. injections over weekly oral tablets.
In all countries, except Switzerland where no statistical
differences were observed, patients disliked being at
risk of gastrointestinal disorders more than being at risk
of skin reactions and flu-like symptoms. The two param-
eters for the side effects attribute had a positive sign,
indicating that patients disliked being at risk of gastroin-
testinal disorders more than being at risk of skin reactions
and flu-like symptoms. Standard deviations parameters
were significant for most of the attributes in all countries,
indicating the presence of preference heterogeneity be-
tween patients, and hence variations in the importance
of the attributes/levels.
There were statistical significant differences for 13 out
of 42 attribute/levels interactions between countries
(Table 4). Countries with the largest sample were used
as a reference, that is, Belgium for countries with the
cost attribute and the Netherlands for those without, re-
spectively. In comparison with Belgium, patients in Ireland
had a significantly stronger preference for i.v. every
3 months or yearly, and preferred being at risk for flu-
like symptoms and skin reactions compared with gastro-
intestinal disorders. In Switzerland, a significantly higher
value was attached to s.c. administration every 6 months
and yearly i.v. administration compared with Belgium,
while a monthly oral tablet was significantly less preferred.
In comparison with the Netherlands, patients in France,
UK and Spain are found to have only a few significant
interaction differences. For example, in the UK, a monthly
oral tablet was significantly less preferred while i.v. admin-
istration every 3 months was significantly more preferred.
Efficacy was less preferred in France and Spain than in the
Netherlands.
The presence of previous fractures significantly reduced
the importance of the cost attribute in two of the three
countries with a cost attribute (see supplementary Table
S1, available at Rheumatology Online). In Belgium and
Switzerland, patients with previous fractures are willing
to pay more for osteoporosis medication than patients
without fractures. In countries without the cost attribute,
the presence of a previous fracture was shown to posi-
tively and significantly affect the importance of drug ef-
fectiveness, with the exception of France.
Discussion
This study used a DCE to evaluate the preferences of
patients with, or at risk of, osteoporosis for medication
attributes in seven European countries. In line with a pre-
vious study conducted in Belgium only [8], osteoporotic
patients across Europe trade between attributes when
making treatment choices, and all attributes were
TABLE 2 Patients’ characteristics
Socio-demographics
and health characteristics
Countries with cost attribute Countries without cost attribute
Belgium
(n = 257)
Ireland
(n = 200)
Switzerland
(n = 98)
France
(n = 100)
Netherlands
(n = 188)
Spain
(n = 183)
UK
(n = 100)
Age, mean (S.D.), years 67.1 (10.4) 63.9 (11.9) 62.6 (9.3) 67.8 (11.0) 65.3 (11.9) 59.2 (9.8 71.1 (8.4)
Female gender 83.3 86.8 81.1 88.4 78.1 91.1 91.9
Educational level, %
Primary 8.4 19.4 10.2 5.3 12.7 23.4 3.0
Some high school 35.9 25.0 15.3 31.6 36.4 10.8 55.0
High-school graduate 30.3 29.6 36.7 14.7 28.8 32.9 20.0
College or University 25.5 26.0 37.8 48.4 22.0 32.9 22.0
Diagnosis of osteoporosis, % 89.8 45.9 93.3 94.7 70.0 54 93
Years since osteoporosis,
mean (S.D.)
8.9 (6.1) 5.4 (5.1) 7.4 (5.7) 9.0 (8.8) 4.7 (5.6) 8.9 (10.5) 8.8 (6.5)
With prior fracture(s), % 52.5 45.3 53.7 71.2 61.6 33.8 60.2
Patients on osteoporotic
treatment, %
69.8 37.8 74.4 65.6 50.7 38.2 65.3
Administration mode of
current treatment, %
Oral 72.2 41.3 65.7 75.4 73.5 86.0 81.5
s.c. 15.4 42.7 11.4 1.9 15.7 4.0 6.1
i.v. 12.4 16.0 22.9 22.6 10.8 10.0 12.3
Testretest, % 85.2 89.4 81.6 88.9 93.6 80.9 84.0
Task difficulty, range 17 3.35 2.66 2.94 2.77 3.41 3.05 2.62
www.rheumatology.oxfordjournals.org 1171
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significant and thus important for patients’ decisions. As
expected, patients preferred higher efficacy and lower
costs; and mode of administration was an important attri-
bute for patients [17, 20]. In all countries, patients pre-
ferred on average a 6-monthly s.c. injection compared
with a weekly oral tablet, and in some countries, patients
also preferred a monthly oral tablet or yearly intravenous
administration compared with weekly oral tablets.
To the best of our knowledge, this study is one of the
first DCE studies that have elicited preferences across
several countries [21] and therefore provides information
on the comparability of patients’ preferences across
countries, and it is the first to do so for osteoporosis.
Our study suggests that patients’ preferences for osteo-
porosis drug therapy are the same on many key attributes
for several European countries, although some statistical
differences between countries were observed for a small
number of attributes, especially modes of administration.
Depending on policy objectives, this may imply that a pan-
European policy could be promoted or that local
FIG. 2 Preferences of osteoporotic patients for mode of administration per country
OT: oral tablet; W: weekly; M: monthly; Y: yearly; SC: subcutaneous; Int: intravenous.
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differences in policy may be facilitated. Further work on
the transferability of patients’ preferences between coun-
tries would be needed to assess whether individual pa-
tients’ characteristics or system level factors, such as
jurisdiction, affect preferences. Of note, in this study we
did not investigate the underlying drivers of preference
differences between countries. Nevertheless, this study’s
finding emphasized that international treatment recom-
mendations should allow for local adaptation and high-
lighted the importance of accounting for individual
preferences in policies that aim to improve the quality of
clinical care for patients with osteoporosis. Our study re-
vealed that the effect of one covariate (previous fractures)
on preferences was not the same across countries.
Previous fractures only affected the cost attribute in coun-
tries where patients pay an out-of-pocket payment, but
they affected preferences for treatment effectiveness in
countries with no out-of-pocket payment. This trend was
not found in all the countries. The impact of covariates on
preferences could not be transferable between countries.
The substantive results from this international study
could be very useful for health professionals and deci-
sion-makers, especially given the poor adherence to
weekly oral regimens, which substantially affects the clin-
ical and economic burden of these medications [22, 23].
Our study suggests that in all countries patients preferred
on average 6-month s.c. injection compared with a weekly
oral tablet, and in some countries, they also preferred a
monthly oral tablet or yearly intravenous administration
compared with a weekly oral tablet. Treatment that is in
line with what patients prefer would increase patient sat-
isfaction with, as well as trust in, their health care and
potentially lead to improved adherence [5]. We also
found that preferences elicited at the group level show
large variance around the estimated coefficients, indicat-
ing heterogeneity in preferences between patients.
For clinical practice, this indicates that tools are needed
to reveal individual patients’ preferences and to support
shared decision-making. These tools should balance drug
effectiveness against patients’ beliefs and preferences
[17]. Several decision aids are already available in osteo-
porosis to support the decision of whether to start an oral
bisphosphonate or not, or how to select an appropriate
medication [2426]. The use of decision aids has the po-
tential to be cost-effective [27], and our results suggest
that tailoring treatments to individual patients can increase
their satisfaction with the treatment. As such, our findings
might assist decision-makers to identify treatments that
are more likely to be cost-effective in practice [9].
Our study has some limitations. First, although we used a
rigorous method to define attributes and levels, some de-
cisions were made to focus on specific aspects of the re-
search question. We focused on the nature of common
side effects and not on their frequency or on more severe
but rare side effects. Rare adverse events such as osteo-
necrosis of the jaw and atypical femoral fracture [28] could
occur with osteoporosis medications. They are infrequent
in all categories of osteoporosis medications and therefore
patients’ preferences would probably not differentiate be-
tween drugs for this reason. Alarming information in the
media on these side effects could perhaps, however, influ-
ence patients’ choices and lead to subjective perception. A
second potential limitation is that data collection was per-
formed in 2012, and treatment patterns could have chan-
ged since then. Temporal variations in preferences need to
be better understood, particularly as patients’ preferences
could change over the course of treatment [9]. Third, we
did not incorporate all types of osteoporosis medications in
our study and focused on common osteoporosis medica-
tions. For example, the daily subcutaneous injection of ter-
iparatide (only prescribed under specific conditions for
patients with severe osteoporosis), or the oral administra-
tion of a dissolved powder (strontium ranelate) were not
included. Fourth, in most countries in our research, the
TABLE 4 Interaction models to assess differences between countries with and without cost attributes
Attributes and levels
Countries with cost
(reference = Belgium)
Countries without cost
(reference = Netherlands)
Ireland Switzerland France Spain UK
Constant +
Efficacy (1% risk reduction)   
Cost per month (E1 or CHF1)   
Mode of administration
Monthly oral tablet  
s.c. 3-monthly
s.c. 6-monthly +
i.v. 3-monthly + +
i.v. yearly + +
Side effects
Flu-like symptoms + 
Skin reactions +
+: above average reference country (P < 0.05); : below average reference country (P< 0.05); : no cost attribute in these
countries (P < 0.05).
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study was only conducted in one centre; we therefore ac-
knowledge that the data may not be generalizable to all
individuals from the country. Fifth, despite the care taken
in translation and adaptation of the survey instrument,
including the use of a medical translation company
specializing in the translation of patient-reported outcome
measures, and a further check and approbation by two
native speakers per version, the questionnaire was not
back-translated. It is therefore possible that patients’
understanding of the descriptions slightly differed between
language versions. Sixth, while DCEs are widely used, an
inherent limitation is that respondents are evaluating hypo-
thetical medications. Therefore, what respondents declare
they will do may potentially be different from what they
would actually do if faced with the choice in real life.
Some studies about the external validity of DCEs have al-
ready been conducted in health care [28, 29] but this has
not yet occurred in the field of osteoporosis. Previous stu-
dies have suggested that predicted and actual treatment
choices could differ at the individual level and that further
work needs to be done to understand the reasons for these
differences [29, 30]. Combining stated preference with
actual choice data in osteoporosis would therefore be
interesting in the future [9]. Seventh, the a priori information
used to construct the choice sets was derived from a pilot
study using 10 patients from one country. Although this is a
relatively small number, the results of this pilot were con-
sistent with expectations and guided the subsequent
design of the main experiment. To maintain consistency
across countries, the same design was used in all coun-
tries. Potentially more efficient designs could have been
obtained at the individual country level, but this would
have restricted the comparability of the task between coun-
tries. Finally, although we assessed the impact of previous
fractures on patients’ preferences on a country basis, our
aim was not to assess the impact of additional character-
istics of the individual patient as covariates on the prefer-
ences. Previous studies [12, 18] reported that preferences
could differ between populations, and that factors such as
age, gender, income, education and prior fractures could
affect preferences for osteoporosis medications. Further
work at a country level is needed to assess whether pref-
erences for attributes and levels may not differ according to
a number of factors, such as age and gender.
In conclusion, this study provides evidence that across
seven western European countries osteoporotic patients
are willing to trade efficacy or to pay money for preferred
mode of administration, and that on average patients pre-
ferred 6-monthly s.c. injection over weekly oral tablets. In
addition, our study suggests that the preferences of pa-
tients for many attributes of osteoporotic drug therapy are
similar across seven European countries, but that for
levels of some attributes, significant differences were
observed. The heterogeneity of preferences within each
country highlights the importance of incorporating the
preferences of individual patients in clinical decision-
making, to improve osteoporosis care.
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